Analyst Summary: Tenaya Therapeutics, a clinical-stage biotech company, reported financial results for Q4 and full year ending December 31, 2022. The company completed a follow-on public offering, raising approximately $204 million. Tenaya plans to begin clinical testing of its lead gene therapy candidate, TN-201, in a Phase 1b multi-center, open-label, dose-escalation study in symptomatic adults with MYBPC3-associated HCM in Q3 2023. Moreover, the company expects to report data from both the SAD and MAD stages of the Phase 1 clinical trial for TN-301 in the second half of 2023. Tenaya plans to submit an IND application for TN-401 to the FDA in H2 2023. The company expects that the available cash, cash equivalents, and investments, $294.5 million, will fund the company into the first half of 2025.